Market News AIOpen the app

IKT stock news · Inhibikase Therapeutics, Inc.

Stories about Inhibikase Therapeutics, Inc. (IKT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for IKT

Follow Inhibikase Therapeutics, Inc. (IKT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IKT
Free on the App Store and Google Play, or on the web.
  1. Nov 10, 2026, 4:50 PM ET · Market

    Inhibikase Therapeutics shared its financial results and updates for the quarter ending September 30, 2026.

    Neutral

    Inhibikase said it had released results for the quarter ended September 30, 2026, and shared corporate updates. The filing gives no figures or details, so it shows no clear change for IKT.

  2. Oct 20, 2026, 5:50 PM ET · Market

    Inhibikase Therapeutics, Inc. says some directors and officers are leaving, while new ones are being chosen.

    Neutral

    Inhibikase filed a report on director or officer changes and officer pay. It gives no details showing a business effect, so the report does not change the company's outlook.

  3. Oct 20, 2026, 5:41 PM ET · Market

    Inhibikase Therapeutics has named Scott Wasserman to its Board of Directors.

    Neutral

    Inhibikase added Scott Wasserman to its board as Dennis Berman left. The report says its drug work continues and reports no business change, so the board turnover does not shift the company's outlook.

  4. Sep 8, 2026, 4:50 PM ET · Market

    Inhibikase Therapeutics, Inc. shares new details in a filing with the SEC.

    Neutral

    Inhibikase Therapeutics, Inc. has disclosed new information through a Form 8-K filing with the SEC, including a corporate presentation dated September 2026.